Browse the latest research summaries in the field of oncology for spinal cord injury patients and caregivers.
Showing 51-60 of 144 results
iScience, 2022 • August 19, 2022
Tetraspanins (TSPANs) are a class of four-transmembrane segmented proteins. The precise functions of TSPANs and their roles in pan-cancer are unclear. In this work, we analyzed 24 TSPAN family genes i...
KEY FINDING: TSPAN3-6, TSPAN9-11, TSPAN13-15, TSPAN17, TSPAN31, TSPAN33 are mainly upregulated, and TSPAN2, TSPAN7 are mainly downregulated.
Frontiers in Neurology, 2022 • December 12, 2022
This study analyzed clinical and imaging features of patients with cancer-related cryptogenic stroke (CCS) involving multiple brain circulations, aiming to improve early diagnosis. The research identi...
KEY FINDING: Patients with cancer-related cryptogenic stroke (CCS) exhibited significantly higher levels of D-dimer, fibrin degradation product (FDP), international normalized ratio (INR), neutrophil to lymphocyte ratio (NLR), and platelets to lymphocyte ratio (PLR) compared to non-cancer cryptogenic stroke patients.
Frontiers in Immunology, 2023 • March 29, 2023
This study investigates the role of QPCTL in glioma, finding its expression elevated in tumor tissues and associated with poor prognosis. Bioinformatic analyses reveal QPCTL's involvement in cytokine ...
KEY FINDING: QPCTL expression is higher in glioma tumor tissue compared to normal tissue, and higher expression correlates with high-grade malignancy and advanced tumor stage.
Metabolites, 2023 • August 3, 2023
The study investigates the efficacy of combining a ketogenic diet (KD), metformin (MET), and metronomic cyclophosphamide (CP) as a triple therapy for MYCN-amplified neuroblastoma (NB). Results showed ...
KEY FINDING: MET reduces cell proliferation and mitochondrial respiration in MYCN-amplified NB cell lines.
Discover Oncology, 2023 • August 7, 2023
This study identifies Caveolin-1 (CAV1) as a key gene involved in glioma progression and resistance to oxidative phosphorylation (OXPHOS) inhibitors. The researchers found that CAV1 is highly expresse...
KEY FINDING: CAV1 is highly expressed in gliomas and its expression is positively related with pathological processes, higher CAV1 predicts shorter overall survival.
Journal of Hematology & Oncology, 2024 • March 11, 2024
This study investigates the proteomic landscape of esophageal squamous cell carcinoma (ESCC) in response to anti-PD1 immunotherapy to identify resistance mechanisms and predictive markers. The researc...
KEY FINDING: Immune and mitochondrial functions are associated with ESCC immunotherapy sensitivity.
Frontiers in Pharmacology, 2024 • August 13, 2024
The study introduces Mn-doped ZIF nanozymes as a novel approach to tumor therapy. These nanozymes leverage the high H2O2 concentration in tumor microenvironments to generate hydroxyl radicals, directl...
KEY FINDING: Mn-ZIF nanozymes possess peroxidase (POD) activity, enabling them to oxidize tumor-localized H2O2 into hydroxyl radicals (·OH), effectively killing tumor cells.
Bioeng Transl Med, 2024 • May 1, 2024
The study developed injectable hydrogels for local, controlled release of protein therapeutics into tissue. The hydrogel, featuring slowly hydrolyzing linkers, prolongs the therapeutic effect, minimiz...
KEY FINDING: Anti-CD47 monoclonal antibodies incorporated into subsurface-injected hydrogel solutions exhibited cytotoxic activity against infiltrative high-grade glioma xenografts in the rodent brain.
Neural Regeneration Research, 2015 • February 1, 2015
This study investigated the involvement of the Notch pathway in the development of diffuse spinal cord astrocytomas by injecting CD133+ and CD133− cell suspensions into mice. Results showed xenografts...
KEY FINDING: Xenografts were observed on the brains of mice receiving CD133+ cell suspensions, with Notch-immunopositive expression in these xenografts.
Journal of Neuroinflammation, 2015 • June 11, 2015
This study demonstrates that DRα1-mMOG-35-55, a novel construct, can effectively treat EAE in MHC-mismatched mice by reducing CNS inflammation. The treatment's efficacy is potentially mediated by an i...
KEY FINDING: DRα1-mMOG-35-55 effectively treats EAE in MHC-mismatched C57BL/6 mice by reducing CNS inflammation.